New guidelines urge cardiologists to take the initiative in prescribing SGLT2 inhibitors or GLP1 receptor antagonists to reduce cardiovascular risk in their patients with diabetes. Until now the drugs have been viewed as glucose lowering agents with a ‘bonus’ effect of lowering cardiovascular risk, but now they should be seen as risk-reduction agents in their ...
Cardiologists urged to go it alone with SGLT2 inhibitors in T2D patients
By Michael Woodhead
29 Nov 2018